Skip to main content
Jennifer Amengual, MD, Oncology, New York, NY

JenniferEffieAmengualMD

Oncology New York, NY

Hematologic Oncology

Associate Professor, Medicine, Columbia University College of Physicians and Surg

Overview of Dr. Amengual

Dr. Jennifer Amengual is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital and NewYork-Presbyterian/Columbia University Irving Medical Center. She received her medical degree from New York Medical College and has been in practice 13 years. She is one of 378 doctors at New York-Presbyterian Hospital and one of 116 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center who specialize in Oncology. She has more than 40 publications and over 500 citings.

Education & Training

  • NYU Grossman School of Medicine
    NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 2007 - 2010
  • Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)
    Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 2004 - 2007
  • New York Medical College
    New York Medical CollegeClass of 2004

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2021 - Present
  • NY State Medical License
    NY State Medical License 2007 - 2025
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Strategy for Overcoming Crebbp and EP300 Mutations in Lymphoma: Development of First-in-Class HAT Activators
    Jennifer E Amengual, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies
    Jennifer E. Amengual, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

  • Development of First-in-Class Histone Acetyltransferase (HAT) Activators for Precision Targeting of Epigenetic Derangements in Lymphoma 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Pipeline Moves: Moderna’s Pandemic Influenza Vaccine Trial Completes
    Pipeline Moves: Moderna’s Pandemic Influenza Vaccine Trial CompletesAugust 19th, 2024